用单剂量的皮质类固醇成功治疗早期呈现的输入性受精:一项前性随机对照试验
Tuğba Acer-Demir1, Ayşe Gültekingil2, Ender Fakıoğlu1
1Department of Pediatric Surgery, Başkent University, Ankara, Turkey.
Journal of pediatric surgery
|February 6, 2025
概括
单剂量皮质类固醇治疗显著改善了早期的肠分泌解决与单独观察相比. 这种方法特别有效于大脑内吸收,为减少或手术提供了不那么侵入性的替代方案.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 临床试验 临床试验
- 医疗干预 医疗干预
背景情况:
- 肠接是幼儿的常见外科紧急情况.
- 目前的管理通常涉及水静电或气动减速,或手术.
- 评估非侵入性治疗选择对于早期病例至关重要.
研究的目的:
- 为了比较单剂量皮质类固醇治疗与观察在解决早期内受精的疗效.
- 为了确定皮质类固醇治疗是否可以避免需要减少手术或手术.
- 根据输入接类型 (ileocolic 与 ileoileal) 评估成功率.
主要方法:
- 预期随机对照试验,涉及0-4岁儿童,通过超声波诊断出肠道吸收.
- 形成了两组:一组接受了单次静脉注射甲基prednisolone (1 毫克/公斤),另一组没有药物 (仅供随访).
- 超声波随访平均4小时进行,以评估分辨率.
主要成果:
- 该研究包括60名患者在类固醇组和32名患者在对照组.
- 类固醇治疗的成功率为81.7%,明显高于随访组56.3%的成功率 (p=0.009).
- 对于大耳内肠,类固醇治疗的成功率为77.3%,而对照组的成功率为22.2% (p=0.012).
结论:
- 单剂量甲基普雷迪尼索隆是一种高效的治疗方法,用于早期诊断的内肠,特别是24小时内内耳类型.
- 皮质类固醇治疗可以考虑在伊叶内肠接病例中,这些病例在初始观察时没有得到解决.
- 这种治疗方法为传统的减肥方法提供了一个成功的,不那么侵入性的替代方案.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:21Inflammatory Bowel Disease V: Surgical Management
103
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
103
01:21Drugs for Treatment of Constipation-Predominant IBS
130
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
130
01:29Inflammatory Bowel Disease IV: Pharmacological Management
100
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
100
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141